Bristol Plans Plavix Price Increase Next Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb is supporting Plavix "full steam" with DTC ads to mitigate impact from generic clopidogrel.
You may also be interested in...
Bristol Director Cornelius Will Serve As Interim CEO
Bristol’s Board of Directors announces CEO Peter Dolan to leave, effective immediately, as well as general counsel Richard Willard.
Bristol Lowers EPS Guidance On Plavix Decision
Bristol-Myers Squibb downgraded its full year eps guidance by up to 24% based on the impact of Apotex' launch of generic clopidogrel.
Plavix Patent Infringement Trial Set For Jan. 22
Sanofi/Bristol demonstrated that Apotex patent invalidity defense "lacks substantial merit," according to a court ruling granting a preliminary injunction blocking generics.